Lerch E, Müller U R
Division of Internal Medicine, Zieglerspital, Bern, Switzerland.
J Allergy Clin Immunol. 1998 May;101(5):606-12. doi: 10.1016/S0091-6749(98)70167-8.
Venom immunotherapy (VIT) protects most patients allergic to Hymenoptera stings while booster injections are continued. Few data on long-term protection after discontinuation of treatment are available.
We sought to investigate protection from re-stings over a prolonged period after stopping VIT.
Re-sting data were obtained from 200 of 322 patients in whom VIT had been stopped between 1988 and 1992 after a duration of at least 3 years. The 25 (12.5%) patients who again developed systemic allergic reactions were compared with 50 matched patients without re-sting reactions. Clinical data and diagnostic parameters (i.e., skin sensitivity and specific IgE and IgG) were studied.
Of the 25 patients who had re-sting reactions, 19 had been treated with bee venom (relapse rate, 15.8%), and six had been treated with Vespula venom (relapse rate, 7.5%). About half of the re-sting reactions occurred on the first resting after stopping VIT. Most of these reactions were mild, whereas the majority of reactions occurring after repeated re-stings were severe. When re-sting reactions were related to the total re-stings per year, an accumulation of sting reactions was observed in years 3 to 5 after stopping VIT. Patients with re-sting reactions had been receiving VIT for a significantly shorter duration (43.35 months) than those with continued protection (54.65 months) (p < 0.01). Of the diagnostic parameters, only a negative intracutaneous skin test at 10(-3) gm/L predicted long-term protection reliably.
Venom immunotherapy of 3 to 5 years duration induces long-term protection in most patients. In rare occasions severe re-sting reactions may, however, occur, especially after repeated re-stings.
毒液免疫疗法(VIT)在持续进行加强注射时可保护大多数对膜翅目昆虫叮咬过敏的患者。关于停止治疗后的长期保护的数据很少。
我们试图研究停止VIT后长时间内免受再次叮咬的保护情况。
从1988年至1992年期间停止VIT且疗程至少为3年的322例患者中的200例获取再次叮咬数据。将再次发生全身过敏反应的25例(12.5%)患者与50例匹配的无再次叮咬反应的患者进行比较。研究临床数据和诊断参数(即皮肤敏感性以及特异性IgE和IgG)。
在有再次叮咬反应的25例患者中,19例接受过蜂毒治疗(复发率15.8%),6例接受过黄蜂毒液治疗(复发率7.5%)。约一半的再次叮咬反应发生在停止VIT后的首次叮咬时。这些反应大多为轻度,而在多次再次叮咬后发生的反应多数为重度。当再次叮咬反应与每年的总叮咬次数相关时,在停止VIT后的第3至5年观察到叮咬反应的累积。有再次叮咬反应的患者接受VIT的疗程(43.35个月)明显短于有持续保护的患者(54.65个月)(p<0.01)。在诊断参数中,仅10(-3)g/L时的阴性皮内皮肤试验能可靠地预测长期保护。
持续3至5年的毒液免疫疗法可使大多数患者获得长期保护。然而,在极少数情况下可能会发生严重的再次叮咬反应,尤其是在多次再次叮咬后。